Drug Type Live biotherapeutic products |
Synonyms Live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum [L. citreum]), LB P8, LB-P8 |
Target- |
Mechanism Bacteria replacements, Gastrointestinal microbiome modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cholangitis, Sclerosing | Phase 2 | KR | LISCure Bioscience Co. Ltd.Startup | - |
Cholestatic liver disease | Phase 1 | KR | LISCure Bioscience Co. Ltd.Startup | 30 Jan 2022 |
Nonalcoholic Steatohepatitis | Phase 1 | AU | LISCure Bioscience Co. Ltd.Startup | 04 Jan 2022 |
Rheumatoid Arthritis | Phase 1 | AU | LISCure Bioscience Co. Ltd.Startup | 04 Jan 2022 |